Repligen Corporation (RGEN) Shares Bought by Pacad Investment Ltd.
Pacad Investment Ltd. grew its holdings in Repligen Corporation (NASDAQ:RGEN) by 65.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,800 shares of the biotechnology company’s stock after acquiring an additional 1,900 shares during the period. Pacad Investment Ltd.’s holdings in Repligen Corporation were worth $199,000 as of its most recent filing with the Securities & Exchange Commission.
Other institutional investors have also made changes to their positions in the company. Benin Management CORP bought a new stake in shares of Repligen Corporation in the second quarter worth about $207,000. Jennison Associates LLC bought a new stake in shares of Repligen Corporation in the second quarter worth about $291,000. Karp Capital Management Corp bought a new stake in shares of Repligen Corporation in the first quarter worth about $506,000. Invictus RG bought a new stake in shares of Repligen Corporation in the first quarter worth about $233,000. Finally, Geode Capital Management LLC increased its holdings in shares of Repligen Corporation by 8.2% in the first quarter. Geode Capital Management LLC now owns 323,737 shares of the biotechnology company’s stock worth $11,395,000 after purchasing an additional 24,591 shares during the last quarter. Institutional investors and hedge funds own 97.91% of the company’s stock.
WARNING: “Repligen Corporation (RGEN) Shares Bought by Pacad Investment Ltd.” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/14/repligen-corporation-rgen-shares-bought-by-pacad-investment-ltd.html.
Several equities research analysts have recently issued reports on RGEN shares. Janney Montgomery Scott lifted their target price on Repligen Corporation from $42.00 to $47.00 in a report on Friday, June 23rd. TheStreet raised Repligen Corporation from a “c+” rating to a “b-” rating in a report on Friday, August 11th. Zacks Investment Research raised Repligen Corporation from a “hold” rating to a “buy” rating and set a $46.00 target price on the stock in a report on Saturday, August 12th. BidaskClub raised Repligen Corporation from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. Finally, Jefferies Group LLC reaffirmed a “hold” rating and issued a $40.00 target price (up from $33.00) on shares of Repligen Corporation in a report on Wednesday, June 28th. Three investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. Repligen Corporation currently has a consensus rating of “Buy” and an average price target of $42.00.
Shares of Repligen Corporation (RGEN) opened at 43.00 on Thursday. The stock has a 50 day moving average price of $41.85 and a 200 day moving average price of $38.55. Repligen Corporation has a one year low of $26.16 and a one year high of $46.81. The company has a market capitalization of $1.61 billion, a PE ratio of 84.15 and a beta of 1.21.
Repligen Corporation (NASDAQ:RGEN) last issued its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported $0.20 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.15 by $0.05. The firm had revenue of $32.40 million for the quarter, compared to analyst estimates of $31.72 million. Repligen Corporation had a net margin of 15.61% and a return on equity of 9.90%. Repligen Corporation’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period last year, the company posted $0.16 EPS. On average, equities research analysts predict that Repligen Corporation will post $0.59 earnings per share for the current year.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products.
Want to see what other hedge funds are holding RGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Repligen Corporation (NASDAQ:RGEN).
Receive News & Stock Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related stocks with our FREE daily email newsletter.